• Sulfachloropyridazine: Mechanism, Evidence, and Research Uti

  2026-07-20

  Sulfachloropyridazine is a broad-spectrum sulfonamide antibacterial agent used in microbiological research. It inhibits bacterial folate synthesis through competitive DHPS inhibition, with potent, strain-dependent effects on diverse pathogens. Recent studies highlight its role in microbial ecology and in vivo infection models.

• Salvianolic Acid B Inhibits LH2 to Reduce Collagen in Pulmon

  2026-07-19

  This study demonstrates that Salvianolic acid B (Dan Shen Suan B) serves as a targeted inhibitor of lysyl hydroxylase 2 (LH2), reducing pathological collagen cross-linking and deposition in pulmonary fibrosis. The findings offer mechanistic evidence for the compound's antifibrotic activity and highlight its translational potential as an extracellular matrix remodeling agent.

• n-Dodecyl-β-D-maltoside (C4421): Reliable Membrane Protein A

  2026-07-18

  This article provides a scenario-driven, evidence-based guide for biomedical researchers seeking reproducibility in membrane protein workflows using n-Dodecyl-β-D-maltoside (SKU C4421). Drawing on real laboratory challenges, we demonstrate how DDM enhances solubilization, protein stability, and assay fidelity, with actionable recommendations supported by recent structural biology breakthroughs.

• Sulfachloropyridazine Modulates Microbiota in E. tenella Inf

  2026-07-17

  This study provides an integrated analysis of sulfachloropyridazine and ethanamizuril, alone and in combination, on the cecal microbial and metabolomic profiles of chickens infected with Eimeria tenella. The findings clarify drug-specific impacts on pathogenic bacteria and metabolic perturbations, informing targeted antimicrobial and infection model studies.

• Artemisinin Mitigates Diabetic Cognitive Decline via NRF2 Re

  2026-07-17

  Wang et al. (2024) provide compelling evidence that artemisinin alleviates cognitive impairment in type 2 diabetic mice by activating NRF2 and suppressing neuronal ferroptosis in the hippocampus. Their work highlights the mechanistic role of NRF2 signaling pathway inhibition and ferroptosis modulation in diabetic cognitive deficits, suggesting new avenues for neuroprotective intervention.

• BAY-826: Potent Small Molecule Inhibitor for Retinal Models

  2026-07-16

  BAY-826 streamlines retinal neurovascular research by enabling precise, nanomolar inhibition of critical signaling nodes in angiopoietin and PEDF pathways. Its high selectivity and robust performance empower advanced co-culture and hypoxia assays, with flexible workflows and reproducible results.

• HBTU Chemistry: Elevating Peptide Probe Design for Translati

  2026-07-16

  This article bridges mechanistic insights with strategic guidance for researchers leveraging HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) in advanced peptide synthesis. Drawing on the synthesis of caged bioluminescent probes for immunoproteasome research, we explore how HBTU’s unique properties enable efficient, racemization-resistant peptide bond formation—crucial for next-generation disease probes. The discussion integrates recent protocol innovations, comparative reagent analysis, and actionable guidance for translational scientists seeking reliable, high-fidelity peptide constructs.

• EZ Cap EGFP mRNA 5-moUTP: High-Fidelity mRNA Delivery Workfl

  2026-07-15

  EZ Cap™ EGFP mRNA (5-moUTP) offers unmatched translation efficiency and immune evasion for gene expression studies. This advanced mRNA unlocks robust in vitro and in vivo imaging, streamlining experimental workflows and troubleshooting for reproducible, high-fidelity results.

• CCR3-Targeted Cyclic Peptides Inhibit Angiogenesis in AMD Mo

  2026-07-15

  This study introduces CCR3-targeted cyclic peptides as a novel therapeutic approach for age-related macular degeneration (AMD), demonstrating inhibition of pathological angiogenesis and protection of retinal photoreceptors. The optimized peptide IB-2 shows efficacy in both in vitro and in vivo models, offering a potential alternative to anti-VEGF therapies.

• PFHxS-Induced Hepatotoxicity via PPARα Pathway in Zebrafish

  2026-07-14

  This study elucidates how perfluorohexanesulfonic acid (PFHxS), a prevalent short-chain PFAS, induces hepatotoxicity in larval zebrafish through disruption of the PPARα signaling pathway. The findings clarify molecular mechanisms of PFHxS toxicity at environmentally relevant concentrations and provide a robust model for metabolic disease research and environmental toxicology.

• JDJM Suppresses Wnt/β-Catenin Signaling in KOA Synovium: Ins

  2026-07-14

  This study delineates how Jiawei Duhuo Jisheng mixture (JDJM) downregulates the Wnt/β-catenin signaling pathway in synovial fibroblasts from knee osteoarthritis (KOA) models. Through both in vitro and in vivo experiments, JDJM demonstrated significant reduction in pathway mediators and inflammation, highlighting a promising mechanism for KOA intervention.

• Tetraethylammonium Chloride: Precision K+ Channel Blockade W

  2026-07-13

  Tetraethylammonium chloride (TEAC) is the gold standard for dissecting potassium channel function in vascular and metabolic research. This guide delivers actionable workflows, advanced protocol parameters, and troubleshooting strategies to help researchers leverage TEAC’s dual-site blockade for maximal experimental resolution.

• SEMA3E Drives Beige Adipocyte Differentiation via β-Catenin

  2026-07-13

  This study demonstrates that SEMA3E promotes beige adipocyte differentiation and thermogenesis in mice through β-catenin signaling, identifying SEMA3E as a pivotal regulator of adipose tissue plasticity. These findings provide mechanistic insight with implications for metabolic disease research and potential therapeutic strategies targeting adipogenesis.

• Rhodamine B in Precision Cell Imaging: Solubility and Signal

  2026-07-12

  Discover how Rhodamine B (Basic Violet 10) empowers advanced fluorescence microscopy and signal amplification workflows. This article uniquely explores solubility, storage, and mechanistic insights critical for reproducible and high-sensitivity cell labeling.

• WEHI-539: Precision BCL-XL Inhibitor for Apoptosis Research

  2026-07-10

  WEHI-539 stands out as a highly selective BCL-XL inhibitor, empowering researchers to dissect apoptotic resistance and sensitize cancer stem cells with unmatched specificity. This guide details optimized workflows, troubleshooting strategies, and actionable insights to maximize experimental reproducibility using APExBIO's WEHI-539.

8743 records 12/583 page Previous Next First page 上5页 1112131415 下5页 Last page